[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

High scFv–receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus

Cancer Gene Therapy volume 21, pages 256–260 (2014)Cite this article

Subjects

Abstract

The relationship between ligand–receptor affinity and antitumor potency of an oncolytic virus was investigated using a panel of six HER2/neu (HER2)-targeted measles viruses (MVs) displaying single-chain antibodies (scFv) that bind to the same epitope on HER2, but with affinities ranging from 10−6 to 10−11 M. All viruses were able to infect SKOV3ip.1 human ovarian cancer cells in vitro, but only the high-affinity MV (Kd ⩾10−8 M) induced cytopathic effects of syncytia formation in the cell monolayers. In contrast, all six viruses were therapeutically active in vivo against orthotopic human ovarian SKOV3ip.1 tumor xenografts in athymic mice compared with saline-treated controls. The oncolytic activities of MV displaying the high-affinity scFv (Kd=10−9, 10−10, 10−11 M) were not significantly superior to MV displaying scFv with Kd of 10−8 M or less. Results from this study suggest that increasing the receptor affinity of the attachment protein of an oncolytic MV has minimal impact on its in vivo efficacy against a tumor that expresses the targeted receptor.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Russell SJ, Peng KW, Bell JC . Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658–670.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Russell SJ, Peng KW . Viruses as anticancer drugs. Trends Pharmacol Sci 2007; 28: 326–333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Beatty MS, Curiel DT . Chapter two–adenovirus strategies for tissue-specific targeting. Adv Cancer Res 2012; 115: 39–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bergman I, Whitaker-Dowling P, Gao Y, Griffin JA, Watkins SC . Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells. Virology 2003; 316: 337–347.

    Article  CAS  PubMed  Google Scholar 

  5. Ayala-Breton C, Barber GN, Russell SJ, Peng KW . Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther 2012; 23: 484–491.

    Article  CAS  PubMed  Google Scholar 

  6. Msaouel P, Iankov ID, Dispenzieri A, Galanis E . Attenuated oncolytic measles virus strains as cancer therapeutics. Curr Pharm Biotechnol 2012; 13: 1732–1741.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Russell SJ, Peng KW . Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009; 330: 213–241.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Ong HT, Timm MM, Greipp PR, Witzig TE, Dispenzieri A, Russell SJ et al. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol 2006; 34: 713–720.

    Article  CAS  PubMed  Google Scholar 

  9. Anderson BD, Nakamura T, Russell SJ, Peng KW . High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004; 64: 4919–4926.

    Article  CAS  PubMed  Google Scholar 

  10. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23: 209–214.

    Article  CAS  PubMed  Google Scholar 

  11. Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I et al. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res 2013; 73: 865–874.

    Article  CAS  PubMed  Google Scholar 

  12. Friedrich K, Hanauer JR, Prufer S, Munch RC, Volker I, Filippis C et al. DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther 2013; 21: 849–859.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yaiw KC, Miest TS, Frenzke M, Timm M, Johnston PB, Cattaneo R . CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy. Gene Ther 2011; 18: 313–317.

    Article  CAS  PubMed  Google Scholar 

  14. Bossow S, Grossardt C, Temme A, Leber MF, Sawall S, Rieber EP et al. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther 2011; 18: 598–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW . Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 2009; 69: 1128–1141.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hasegawa K, Nakamura T, Harvey M, Ikeda Y, Oberg A, Figini M et al. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 2006; 12 (20 Pt 1): 6170–6178.

    Article  CAS  PubMed  Google Scholar 

  17. Gutierrez C, Schiff R . HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 2011; 135: 55–62.

    PubMed  PubMed Central  Google Scholar 

  18. Raspollini MR, Amunni G, Villanucci A, Castiglione F, Degl'Innocenti DR, Baroni G et al. HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival. Appl Immunohistochem Mol Morphol 2006; 14: 181–186.

    Article  PubMed  Google Scholar 

  19. Zhou BP, Hung MC . Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 2003; 30 (5 Suppl 16): 38–48.

    Article  CAS  PubMed  Google Scholar 

  20. Iwamoto H, Fukasawa H, Honda T, Hirata S, Hoshi K . HER-2/neu expression in ovarian clear cell carcinomas. Int J Gynecol Cancer 2003; 13: 28–31.

    Article  CAS  PubMed  Google Scholar 

  21. Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ, Peng KW . Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol 2007; 81: 13149–13157.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Reisoli E, Gambini E, Appolloni I, Gatta V, Barilari M, Menotti L et al. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice. Cancer Gene Ther 2012; 19: 788–795.

    Article  CAS  PubMed  Google Scholar 

  23. Magnusson MK, Kraaij R, Leadley RM, De Ridder CM, van Weerden WM, Van Schie KA et al. A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer. Hum Gene Ther 2012; 23: 70–82.

    Article  CAS  PubMed  Google Scholar 

  24. Belousova N, Mikheeva G, Xiong C, Soghomonian S, Young D, Le Roux L et al. Development of a targeted gene vector platform based on simian adenovirus serotype 24. J Virol 2010; 84: 10087–10101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Menotti L, Cerretani A, Hengel H, Campadelli-Fiume G . Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol 2008; 82: 10153–10161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Bergman I, Griffin JA, Gao Y, Whitaker-Dowling P . Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int J Cancer 2007; 121: 425–430.

    Article  CAS  PubMed  Google Scholar 

  27. Jelovac D, Emens LA . HER2-directed therapy for metastatic breast cancer. Oncology (Williston Park) 2013; 27: 166–175.

    Google Scholar 

  28. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996; 263: 551–567.

    Article  CAS  PubMed  Google Scholar 

  29. Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M et al. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol 1996; 255: 28–43.

    Article  CAS  PubMed  Google Scholar 

  30. Adams GP, Schier R . Generating improved single-chain Fv molecules for tumor targeting. J Immunol Methods 1999; 231: 249–260.

    Article  CAS  PubMed  Google Scholar 

  31. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998; 58: 485–490.

    CAS  PubMed  Google Scholar 

  32. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ . Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62: 4656–4662.

    CAS  PubMed  Google Scholar 

  33. Ivascu A, Kubbies M . Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis. JBiomol Screen 2006; 11: 922–932.

    Article  CAS  Google Scholar 

  34. Dorig RE, Marcil A, Chopra A, Richardson CD . The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993; 75: 295–305.

    Article  CAS  PubMed  Google Scholar 

  35. Tatsuo H, Ono N, Tanaka K, Yanagi Y . SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000; 406: 893–897.

    Article  CAS  PubMed  Google Scholar 

  36. Noyce RS, Richardson CD . Nectin 4 is the epithelial cell receptor for measles virus. Trends Microbiol 2012; 20: 429–439.

    Article  CAS  PubMed  Google Scholar 

  37. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L . Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9: 16–32.

    Article  CAS  Google Scholar 

  38. Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE . Overexpression of HER-2 in ovarian carcinomas. Cancer Res 2001; 61: 2420–2423.

    CAS  PubMed  Google Scholar 

  39. Rudnick SI, Adams GP . Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 2009; 24: 155–161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998; 77: 1405–1412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61: 4750–4755.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work is supported by grants from the National Institutes of Health/National Cancer Institutes (R01CA118488, R01CA129193 and R01CA129966).

Author information

Authors and Affiliations

  1. Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA

    L Suksanpaisan, S J Russell & K-W Peng

  2. Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA

    S J Russell

  3. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA

    K-W Peng

Authors
  1. L Suksanpaisan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S J Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K-W Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K-W Peng.

Ethics declarations

Competing interests

Dr SJR and Dr K-WP and Mayo Clinic have financial interests in the technology used in this research.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suksanpaisan, L., Russell, S. & Peng, KW. High scFv–receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus. Cancer Gene Ther 21, 256–260 (2014). https://doi.org/10.1038/cgt.2014.25

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2014.25

Search

Advanced search

Quick links